Legal & General Group
MREO

Legal & General Group’s Mereo BioPharma MREO Stock Holding History

Legal & General Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52,179
Closed -$58K – 3605
2022
Q1 		$58K Hold
52,179
– – ﹤0.01% 2977
2021
Q4 		$84K Buy
52,179
+31,867
+157% +$63.7K ﹤0.01% 2946
2021
Q3 		$49K Buy
20,312
+4,595
+29% +$12.2K ﹤0.01% 2980
2021
Q2 		$50K Buy
+15,717
New +$52.7K ﹤0.01% 2950

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Legal & General Group's MREO Position: Q2 2022 in Review

Legal & General Group sold out of Mereo BioPharma (MREO) in Q2 2022, closing a stake of 52,179 shares — an estimated $58K sold.

Legal & General Group first reported a position in MREO in Q2 2021 and held it in 4 quarters. The position peaked at $84K in Q4 2021. 64 funds tracked by Wall St. Rank hold MREO as of Q2 2022.

  • Legal & General Group reported no remaining Mereo BioPharma position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 52,179 Mereo BioPharma shares in Q2 2022, an estimated $58K.
  • Legal & General Group first reported a position in Mereo BioPharma in Q2 2021 and held it in 4 quarters.
  • Legal & General Group's Mereo BioPharma position peaked at $84K in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.